The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B
スポンサーリンク
概要
- 論文の詳細を見る
- 2004-03-01
著者
-
SHINDO Michiko
Liver Diseases Section, Akashi Municipal Hospital
-
HAMADA Kazushige
Kyoto Institute of Technology
-
OKUNO Tadao
Liver Diseases Section, Akashi Municipal Hospital
-
Okuno Tadao
Liver Diseases Section Akashi Municipal Hospital
-
Okuno Tadao
Division Of Liver Diseases Department Of Internal Medicine Akashi Municipal Hospital
-
Shindo Michiko
Liver Diseases Section Akashi Municipal Hospital
-
Shindo Michiko
Division Of Liver Diseases Department Of Internal Medicine Akashi Municipal Hospital
-
Oda Yoko
Division Of Liver Diseases Department Of Internal Medicine Akashi Municipal Hospital
-
Muramatsu Akira
Division Of Liver Diseases Department Of Internal Medicine Akashi Municipal Hospital
-
HAMADA KAZUSHIGE
Department of Biotechnology, Kyoto Institutes of Technology
-
NISHIOJI KENICHI
Division of Liver Diseases, Department of Internal Medicine, Akashi Municipal Hospital
-
Nishioji Kenichi
Division Of Liver Diseases Department Of Internal Medicine Akashi Municipal Hospital
関連論文
- Biological Significance of AFP Expression in Liver Injury Induced by CCL_4
- Biological Significance of Gap Junctional Formation in Hepatoma Cells
- In vivo interferon system assessed by 2'-5' oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin
- The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B
- Retreatment with interferon in patients with genotype II/1b-related chronic hepatitis C
- Early reduction of infected hepatocytes by activated immunity at the time of interferon withdrawal hepatitis followed by lamivudine administration resulted in higher seroconversion in hepatitis Be antigen-positive patients with chronic hepatitis B
- Long-term follow-up of hepatitis G virus/GB virus C replication in liver during and after interferon therapy in patients coinfected with hepatitis C and G viruses